Pei-Ling Chen, MD, PhD, FCAP, comments on research and treatment for patients with CTCL. “Given the fact that mycosis fungoides is a chronic disease, there’s a need for additional treatments with minimal short- and long-term effects,” explains Dr. Chen. “This [study] is quite important because it’s an important new therapy for early-stage disease patients with minimal adverse effects.”
For the full article click here: FDA Rejects NDA for Synthetic Hypericin in Early-stage Cutaneous T-cell Lymphoma